Unknown

Dataset Information

0

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.

ABSTRACT:

SUBMITTER: Yamaoka T 

PROVIDER: S-EPMC7653124 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer.

Yamaoka Toshimitsu T   Tsurutani Junji J   Sagara Hironori H   Ohmori Tohru T  

Translational lung cancer research 20201001 5

Similar Datasets

Unknown Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target <i>HER2</i> Bypass Track Resistance in <i>EGFR</i> Mutation-Positive NSCLC.
| S-EPMC10074240 | biostudies-literature
Unknown EGFR G796D mutation mediates resistance to osimertinib.
| S-EPMC5564797 | biostudies-literature
Unknown Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR.
| S-EPMC12686637 | biostudies-literature
Unknown Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
| S-EPMC6938756 | biostudies-literature
Unknown Treating <i>EGFR</i> mutation resistance in non-small cell lung cancer - role of osimertinib.
| S-EPMC5536882 | biostudies-literature
Unknown Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
| S-EPMC5989837 | biostudies-literature
Unknown Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC.
| S-EPMC8536603 | biostudies-literature
Unknown <i>EGFR</i> mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients.
| S-EPMC7354104 | biostudies-literature
Unknown Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion.
| S-EPMC10864115 | biostudies-literature
Unknown Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.
| S-EPMC10184309 | biostudies-literature